Employer plans are dropping GLP-1 coverage in 2026. How to keep getting Wegovy or Zepbound without insurance: self-pay prices, appeals, same-day prescribing.
If your employer's health plan stopped covering Wegovy or Zepbound at renewal, you do not have to stop treatment. Both manufacturers now sell directly to patients at fixed cash prices, Wegovy through NovoCare Pharmacy and Zepbound through LillyDirect's self-pay program. You still need a valid prescription, but you no longer need your insurance plan to say yes.
GLP-1 coverage is one of the first things employers cut when plan costs rise, and many members are finding out at the start of a new plan year, often mid-treatment. Stopping abruptly matters clinically: weight regain after discontinuation is common and well documented, and restarting later can mean going back through dose titration. Keeping treatment continuous, if it is working for you, is usually the better medical outcome, and it is now realistic to do without insurance.
There are really four paths, and they are not equally worth your time. An appeal is only worth fighting in specific situations. A covered indication you did not know about, like Zepbound's FDA approval for obstructive sleep apnea, can sometimes restore coverage entirely. And the manufacturers' cash prices have come down far enough that self-pay is a workable plan, not a last resort.
Before choosing a path, pin down exactly what your plan did. It changes the answer:
Ask HR or call the number on your insurance card and get the change in writing. Also ask whether the plan offers a transition fill, many plans must give you a short bridge supply at the old terms after a formulary change, which buys you time to sort out the next step without missing doses.
From there, four paths can keep you on treatment. Ranked honestly:
Every plan has an exception process, and you have a legal right to appeal a denial. Be honest with yourself about the odds: if GLP-1s for weight loss were excluded from the plan entirely, an appeal is usually a dead end. If the drug is still covered but you were denied on prior authorization criteria, an appeal with good documentation, BMI history, weight-related conditions, records of what you have already tried, genuinely can work. Your prescriber writes the letter of medical necessity; you file the appeal. Set a deadline for yourself (one round, 30-60 days) so a slow appeal does not become an unplanned gap in treatment.
Novo Nordisk sells Wegovy directly to cash-pay patients through NovoCare Pharmacy, with home delivery. Current published pricing:
Eli Lilly's equivalent program sells Zepbound vials and KwikPens at fixed self-pay prices: $299 per month at 2.5 mg, $399 at 5 mg, and $449 for all doses from 7.5 mg to 15 mg (28-day supply). One catch that matters: to keep the discounted price, you must refill within 45 days of your previous fill. Miss the window and you fall back to a much higher list-based price. Put the refill date in your calendar. Note the vial format at lower doses requires drawing up the dose with a syringe rather than using a pre-set pen, cheaper, slightly more hands-on.
Weight-loss exclusions do not always exclude the same drug for a different diagnosis:
$349 per month for standard pen doses through NovoCare Pharmacy, with a $199/month introductory offer on the two starting doses for new program patients (through December 31, 2026).
$299 to $449 per month by dose through LillyDirect's self-pay program, as long as you refill within 45 days of your previous fill.
You can appeal a denial under existing coverage rules, and those appeals can succeed with good documentation. If the plan excluded the whole drug class at renewal, an appeal rarely changes that, self-pay or a covered indication is usually the more productive route.
Often, yes. OSA is a separate FDA-approved indication, and many plans, including Medicare Part D, cover it when weight-loss coverage is excluded. You need a documented OSA diagnosis, typically from a sleep study.
Self-pay does not mean full-freight. You can generally use HSA or FSA funds for prescription GLP-1s, which pays with pre-tax dollars. And if your plan year resets or you change jobs, re-check coverage, the 2026 landscape is shifting in both directions, and a drug excluded this year is sometimes back the next.
Every path above runs through the same bottleneck: a prescriber. You need one to write the cash-pay prescription NovoCare or LillyDirect will fill, to document an OSA workup, or to back an appeal. Remember that a prescription and insurance coverage are separate things: a licensed clinician can prescribe based on medical appropriateness, and the manufacturer pharmacies fill cash-pay prescriptions directly. That is where Well Revolution fits. Our care is chat-based, no appointments, no video calls, no waiting rooms. Message a licensed US clinician, usually the same day, lay out your situation (what you are on, what dose, what your plan just cut), and get a real plan: a prescription routed for cash-pay fulfillment where appropriate, or straight talk if a different route makes more sense for you. Support is unlimited, so when the 45-day refill window or a dose question comes up later, you message us again, no new visit fee. Availability varies by state, so message us and we'll confirm coverage in your state.
Paying cash for healthcare more broadly? The same logic applies elsewhere, see getting medication without using insurance and what to do when insurance denies a prescription.
Reviewed by PA Michael Rubio, US Medical Director
$80 for the Limited Treatment Plan. If approved, you will receive a 90 day treatment plan with 7 days a week support. Perfect for first time patients who are trying it out.
Or $90 for the Unlimited Membership. If approved, you will receive a full year of care with 7 days a week support, plus unlimited prescriptions, lab tests, imaging orders, letters and referrals with same day care, cancel anytime, no fees. Perfect for established patients looking for full care.
Concerned, need advice, a prescription, refill or referral?
Text a doctor now
